Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone Sodium Phosphate

FDA-approved product (ointment, ophthalmic), marketed as Decadron, Dexacen-4, Dexacort and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Brain edema
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 66 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized Controlled Trial Comparing the Effects of Different Anesthetic Sedatives on PONV in Laparoscopic Cholecystectomy

    NCT07758803 · start 2026-08-15

    Registered record
    Registry ID
    NCT07758803
    Conditions
    Cholelithiasis; Postoperative Nausea and Vomiting
    Interventions
    Propofol; Ciprofol; Remimazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-08-15
    Completion
    2026-10-30
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholelithiasis; Postoperative Nausea and Vomiting
    InterventionPropofol; Ciprofol; Remimazolam
    PhasePhase 4
    Registry statusRecruiting

  • Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage

    NCT07294118 · start 2026-01-02

    Registered record
    Registry ID
    NCT07294118
    Conditions
    Subarachnoid Hemorrhage, Aneurysmal; Headache; Opiate Dependence; Opioid Use
    Interventions
    Lidocaine; Lidocaine and Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-02
    Completion
    2027-08
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage, Aneurysmal; Headache; Opiate Dependence; Opioid Use
    InterventionLidocaine; Lidocaine and Dexamethasone
    PhasePhase 2
    Registry statusRecruiting

  • Intraosseous Versus Submucosal Dexamethsone Injection in Third Molar Surgery

    NCT06720051 · start 2025-06-01

    Registered record
    Registry ID
    NCT06720051
    Conditions
    Third Molar Surgery
    Interventions
    Intraosseous dexamethasone injection after 3rd molar surgery; Submucosal dexamethasone injection after 3rd molar surgery
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-06-01
    Completion
    2025-11-30
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThird Molar Surgery
    InterventionIntraosseous dexamethasone injection after 3rd molar surgery; Submucosal dexamethasone injection after 3rd molar surgery
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

    NCT06192979 · start 2024-01-05

    Registered record
    Registry ID
    NCT06192979
    Conditions
    Amyloidosis; Systemic; AL Amyloidosis
    Interventions
    Daratumumab; Bortezomib; Dexamethasone; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-01-05
    Completion
    2027-03-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Systemic; AL Amyloidosis
    InterventionDaratumumab; Bortezomib; Dexamethasone; Venetoclax
    PhaseNot applicable
    Registry statusRecruiting

  • Two Schemes Response in Multiple Myeloma

    NCT06284395 · start 2023-11-20

    Registered record
    Registry ID
    NCT06284395
    Conditions
    Response, Acute Phase; Survivorship
    Interventions
    Bortezomib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-11-20
    Completion
    2024-10-30
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResponse, Acute Phase; Survivorship
    InterventionBortezomib
    PhaseNot recorded
    Registry statusRecruiting

  • Treating Exacerbations of Asthma With Oral Montelukast in Children

    NCT05819541 · start 2023-10-20

    Registered record
    Registry ID
    NCT05819541
    Conditions
    Status Asthmaticus
    Interventions
    Montelukast Oral Granules; Albuterol; Corticosteroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-10-20
    Completion
    2026-03-26
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStatus Asthmaticus
    InterventionMontelukast Oral Granules; Albuterol; Corticosteroid
    PhasePhase 2
    Registry statusCompleted

  • A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

    NCT05257083 · start 2023-10-10

    Registered record
    Registry ID
    NCT05257083
    Conditions
    Multiple Myeloma
    Interventions
    Daratumumab; Bortezomib; Lenalidomide; Dexamethasone; Cilta-cel; Cyclophosphamide; Fludarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-10-10
    Completion
    2040-08
    Enrolment
    759

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionDaratumumab; Bortezomib; Lenalidomide; Dexamethasone +3 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Prospective Comparative Study Between Ultrasound-guided Continuous Erector Spinae Plane Block and the Use of Intravenous Patient Controlled Analgesia for Management of Pain in Patients With Multiple Fracture Ribs

    NCT05975294 · start 2023-08

    Registered record
    Registry ID
    NCT05975294
    Conditions
    Multiple Fracture Ribs
    Interventions
    amixture 0.125% bupivicaine with fentanyl; 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-08
    Completion
    2024-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Fracture Ribs
    Interventionamixture 0.125% bupivicaine with fentanyl; 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset
    PhaseNot applicable
    Registry statusUnknown

  • Multi-level Molecular Profiling of Stress Exposure Under Standardized Food Intake: A Clinical Study

    NCT06016530 · start 2023-03-21

    Registered record
    Registry ID
    NCT06016530
    Conditions
    Stress Related Disorder; Nutrition, Healthy; Metabolism
    Interventions
    Sleep Deprivation; Dexamethasone Supplementation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-03-21
    Completion
    2025-03-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Related Disorder; Nutrition, Healthy; Metabolism
    InterventionSleep Deprivation; Dexamethasone Supplementation
    PhaseNot applicable
    Registry statusUnknown

  • Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

    NCT04756401 · start 2022-12-08

    Registered record
    Registry ID
    NCT04756401
    Conditions
    Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
    Interventions
    Carfilzomib; Daratumumab; Dexamethasone; Quality-of-Life Assessment; Selinexor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-12-08
    Completion
    2027-12-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
    InterventionCarfilzomib; Daratumumab; Dexamethasone; Quality-of-Life Assessment +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

    NCT05244577 · start 2022-01-18

    Registered record
    Registry ID
    NCT05244577
    Conditions
    Olanzapine; CINV; Testicular Cancer by AJCC V6 and V7 Stage; Cisplatin
    Interventions
    Olanzapine Tablets; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-01-18
    Completion
    2024-03-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOlanzapine; CINV; Testicular Cancer by AJCC V6 and V7 Stage; Cisplatin
    InterventionOlanzapine Tablets; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

    NCT05835726 · start 2022-01-01

    Registered record
    Registry ID
    NCT05835726
    Conditions
    Multiple Myeloma; Daratumumab; Autologous Stem Cell Transplantation; Leukapheresis
    Interventions
    Daratumumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2025-01-31
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Daratumumab; Autologous Stem Cell Transplantation; Leukapheresis
    InterventionDaratumumab
    PhaseNot recorded
    Registry statusCompleted

  • The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

    NCT05143281 · start 2021-12-13

    Registered record
    Registry ID
    NCT05143281
    Conditions
    Cataract
    Interventions
    Dexamethasone 0.4 MG [Dextenza]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-12-13
    Completion
    2023-02-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    InterventionDexamethasone 0.4 MG [Dextenza]
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

    NCT04855136 · start 2021-06-01

    Registered record
    Registry ID
    NCT04855136
    Conditions
    Multiple Myeloma
    Interventions
    BB2121; CC-220; BMS-986405
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-06-01
    Completion
    2025-04-25
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionBB2121; CC-220; BMS-986405
    PhasePhase 1
    Registry statusTerminated

  • Preoperative High-dose Dexamethasone and Emergency Laparotomy

    NCT04791566 · start 2021-03-01

    Registered record
    Registry ID
    NCT04791566
    Conditions
    Intestinal Obstruction and Ileus; Perforated Viscus; Sepsis; Pathophysiology; Inflammatory Response
    Interventions
    Dexamethasone 1 mg/kg; Physiologic saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2022-12-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Obstruction and Ileus; Perforated Viscus; Sepsis; Pathophysiology +1 more
    InterventionDexamethasone 1 mg/kg; Physiologic saline
    PhasePhase 4
    Registry statusCompleted